Edwards Lifesciences Corporation Common Stock vs VanEck Semiconductor ETF — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.42 (market cap $48.56B), while VanEck Semiconductor ETF trades at $602.57 (market cap $73.92B). The key difference: VanEck Semiconductor ETF is the larger of the two by market cap, and VanEck Semiconductor ETF is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| EW | SMH | |
|---|---|---|
Market Cap | $48.56B | $73.92B |
Volume | 6,520,488 | 11,050,892 |
Sector | Health | — |
52-Week High | $95.18 | $668.91 |
52-Week Low | $72.65 | $325.10 |
Enterprise Value | $45.01B | — |
Typical Hold Time | — | 101 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SMH (VanEck Semiconductor ETF) trades at $603.00, down 3.52% on the day, while maintaining a bullish technical signal with strong moving average support. The ETF has delivered exceptional returns, up approximately 69% year-to-date through September 30, 2026, significantly outperforming individual semiconductor leaders like Nvidia. Recent industry developments include AMD's $8.2 billion acquisition of World Labs, expanding AI capabilities, and positive semiconductor market outlooks from major financial institutions.
The semiconductor sector shows strong momentum with Bank of America projecting the global chip market to nearly double by 2030. However, concentration risk in top holdings and potential rotation to equal-weight alternatives present challenges. The ETF's 12% pullback from recent highs offers entry opportunity, though investors should monitor sector rotation trends and geopolitical trade dynamics affecting semiconductor supply chains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →